<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82497">
  <stage>Registered</stage>
  <submitdate>31/12/2007</submitdate>
  <approvaldate>10/01/2008</approvaldate>
  <actrnumber>ACTRN12608000012370</actrnumber>
  <trial_identification>
    <studytitle>Canterbury anti-neutropil cytoplasmic antibody (ANCA) associated vasculitis observational study</studytitle>
    <scientifictitle>Long-term disease outcomes including organ damage and predictors of disease flare in anti-neutropil cytoplasmic antibody (ANCA) associated vasculitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anti-neutropil cytoplasmic antibody (ANCA) associated vasculitidies including Wegeners granulomatosis (WG)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ANCA associated vasculitidies are rare conditions with significant morbidity. We will observe patients indefinitely to determine long-term disease outcomes and predictors of disease relapse</interventions>
    <comparator>Not applicable observational study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>This is an observational study of disease outcomes. Participants will be assessed using a variety of meausres including the SF36, Bath vasculitis activity score for wegeners granulomatosis (BVASWG), vasculitis damage index (VDI) and the disease extent index (DEI).</outcome>
      <timepoint>Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6 monthly</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Response to and complications from therapy. Clinical and laboratory measures will be used to determine complications including bone marrow suppression and infectio rates</outcome>
      <timepoint>Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6 monthly</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease relapse</outcome>
      <timepoint>Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6monthly</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ANCA associated vasculitis defined by American College of Rheumatology (ACR), Chapel Hill Consensus Criteria or Watts 2007 algorithm</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Lisa Stamp</primarysponsorname>
    <primarysponsoraddress>Deparment of Medicine
P.O.Box 4345
Christchurch</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Canterbury Rheumatology Immunology Research Trust</fundingname>
      <fundingaddress>C/- Dr J O'Donnell
Department of Rheumatology Immunology and Allergy
Canterbury Health Laboratories
P.O.Box 151
Christchurch</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr John O'Donnell</sponsorname>
      <sponsoraddress>Department of Rheumatology Immunology and Allergy
Canterbury Health Laboratories
P.O.Box 151
Christchurch</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Wegeners Granulomatosis (WG) and WG-like diseases affect the small/medium sized blood vessels. In Canterbury the prevalence of WG is one of the highest in the world. Despite this, we are reliant on information from the Northern Hemisphere to guide us on outcomes and treatments. Whether there are differences in disease severity, prognostic markers and treatment response between the Northern and Southern Hemispheres is unknown. We wish to undertake an observational study of WG patients in Canterbury to characterise the clinical characteristics, treatments and outcomes and compare them to those in the Northern Hemisphere. In addition we will evaluate whether novel markers in the blood and urine help predict disease relapse. Although WG is a rare condition, the severity, chronicity and treatments have a significant impact on those affected. The ability to better predict disease relapse will potentially avoid exposure to harmful treatments.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>New Zealand Upper South A Ethics Committee.</ethicname>
      <ethicaddress>Ministry of Health
P.O. Box 3877
Christchurch</ethicaddress>
      <ethicapprovaldate>3/12/2007</ethicapprovaldate>
      <hrec>URA/07/10/076</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
P.O.Box 4345
Christchurch</address>
      <phone>+ 64 3 3640 253 </phone>
      <fax>+64 3 3640935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
P.O.Box 4345
Christchurch</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 3640935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
P.O.Box 4345
Christchurch</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 3640935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
POBox 4345
Christchurch 8014</address>
      <phone>+64 3 364 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>